Cell Therapeutics Management Discusses Q4 2012 Results - Earnings Call ... Seeking Alpha As you may recall, this is a randomized trial of pixantrone-rituximab versus gemcitabine-rituximab in patients with aggressive B-cell NHL relapse after receiving CHOP-R therapy or an equivalent regimen and are ineligible for stem cell transplant. The ... |
